Last reviewed · How we verify
RP6530
At a glance
| Generic name | RP6530 |
|---|---|
| Also known as | A dual PI3K delta/gamma inhibitor, PI3K inhibitor, PI3k Delta/ Gamma inhibitor |
| Sponsor | Rhizen Pharmaceuticals SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) (PHASE2)
- Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (PHASE2)
- Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer (PHASE2)
- Compassionate Use Study of Tenalisib (RP6530) (PHASE1, PHASE2)
- Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (PHASE1, PHASE2)
- Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (PHASE2)
- Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (PHASE2)
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RP6530 CI brief — competitive landscape report
- RP6530 updates RSS · CI watch RSS
- Rhizen Pharmaceuticals SA portfolio CI